- JP-listed companies
- Kringle Pharma,Inc.
- Income statement
Kringle Pharma,Inc. (4884) Income statement
Market cap
¥2.7B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
| 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Revenue | - | - | - | - | - | 468 | 290 | 392 | 69 | 80 | 72 |
| Revenue growth (%) | - | - | - | - | - | - | |||||
| Cost of revenue | - | - | - | - | - | - | 72 | - | - | - | - |
| Gross profit | - | - | - | - | - | 468 | 218 | 303 | 69 | 80 | 72 |
| Gross margin (%) | - | - | - | - | - | ||||||
| Operating margin (%) | - | - | - | - | - | ||||||
| Operating expenses | - | - | - | 224 | 372 | 639 | 576 | 730 | 958 | 898 | 982 |
| Operating income | - | - | - | -224 | -372 | -172 | -358 | -426 | -889 | -818 | -909 |
| Income before tax | -198 | 102 | -102 | -64 | -302 | -116 | -300 | -330 | -853 | -755 | -915 |
| Pretax margin (%) | - | - | - | - | - | -24.9 | -103.4 | -84.3 | -1,231.3 | -943.3 | -1,266.7 |
| Provision for income taxes | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Effective tax rate (%) | - | - | - | ||||||||
| Net income | -200 | 100 | -102 | -65 | -302 | -118 | -301 | -332 | -854 | -756 | -916 |
| Net income margin (%) | - | - | - | - | - | ||||||
| Earnings per share | -3,848.72 | 1,925.08 | -1,961.39 | -62.01 | -290.14 | -106.7 | -72.51 | -68.33 | -158.46 | -118.21 | -133.92 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - |